160 related articles for article (PubMed ID: 29090091)
1. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States.
Prabhu VS; Solomkin JS; Medic G; Foo J; Borse RH; Kauf T; Miller B; Sen SS; Basu A
Antimicrob Resist Infect Control; 2017; 6():107. PubMed ID: 29090091
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
Kauf TL; Prabhu VS; Medic G; Borse RH; Miller B; Gaultney J; Sen SS; Basu A
BMC Infect Dis; 2017 Apr; 17(1):314. PubMed ID: 28454524
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
[TBL] [Abstract][Full Text] [Related]
5. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.
Chen GJ; Pan SC; Foo J; Morel C; Chen WT; Wang JT
J Microbiol Immunol Infect; 2019 Oct; 52(5):807-815. PubMed ID: 31029529
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
8. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Eckmann C; Solomkin J
Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
[TBL] [Abstract][Full Text] [Related]
10. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
11. The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
Mikamo H; Monden K; Miyasaka Y; Horiuchi T; Fujimoto G; Fukuhara T; Yoshinari T; Rhee EG; Shizuya T
J Infect Chemother; 2019 Feb; 25(2):111-116. PubMed ID: 30528561
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Jackson CA; Newland J; Dementieva N; Lonchar J; Su FH; Huntington JA; Bensaci M; Popejoy MW; Johnson MG; De Anda C; Rhee EG; Bruno CJ
Pediatr Infect Dis J; 2023 Jul; 42(7):557-563. PubMed ID: 37000942
[TBL] [Abstract][Full Text] [Related]
14. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Grau S; Lozano V; Valladares A; Cavanillas R; Xie Y; Nocea G
Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W; Deng T; Li S; Shu Y; Wu Y
BMC Infect Dis; 2023 Apr; 23(1):256. PubMed ID: 37085768
[TBL] [Abstract][Full Text] [Related]
16. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
Shortridge D; Castanheira M; Pfaller MA; Flamm RK
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953
[TBL] [Abstract][Full Text] [Related]
17. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
[TBL] [Abstract][Full Text] [Related]
18. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
Shortridge D; Streit J; Pfaller M; Tulloch M; Chen WT; Castanheira M
J Glob Antimicrob Resist; 2022 Dec; 31():98-103. PubMed ID: 35988706
[TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Scott LJ
Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
Jansen JP; Kumar R; Carmeli Y
Value Health; 2009; 12(2):234-44. PubMed ID: 20667059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
